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Purpose: Internal mammary lymph node (IMN) involvement is associated with poor prognosis in breast cancer. This study 
investigated the treatment outcomes of initial clinically IMN-positive breast cancer patients who received adjuvant radiotherapy (RT), 
including IMN irradiation, following primary breast surgery. 
Materials and Methods: We retrospectively reviewed data of 95 breast cancer patients with clinically detected IMNs at 
diagnosis treated with surgery and RT between June 2009 and December 2015. Patients received adjuvant RT to the whole breast/
chest wall and regional lymph node (axillary, internal mammary, and supraclavicular) areas. Twelve patients received an additional 
boost to the IMN area. 
Results: The median follow-up was 43.2 months (range, 4.5 to 100.5 months). Among 77 patients who received neoadjuvant 
chemotherapy, 52 (67.5%) showed IMN normalization and 19 (24.6%) showed a partial response to IMN. There were 3 and 24 cases 
of IMN failure and any recurrence, respectively. The 5-year IMN failure-free survival, disease-free survival (DFS), and overall survival 
(OS) were 96%, 70%, and 84%, respectively. IMN failure-free survival was significantly affected by resection margin status (97.7% if 
negative, 87.5% for close or positive margins; p = 0.009). All three patients with IMN failure had initial IMN size ≥1 cm and did not 
receive IMN boost irradiation. The median age of the three patients was 31 years, and all had hormone receptor-negative tumors. 
Conclusion: RT provides excellent IMN control without the support of IMN surgery. Intensity-modulated radiotherapy, including 
IMN boost for breast cancer patients, is a safe and effective technique for regional lymph node irradiation.
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Introduction
The internal mammary lymph node (IMN) is a major lymphatic 
drainage pathway of the breast, draining about 25% of 
breast lymphatics [1,2]. The reported incidence of IMN 
involvement in breast cancer patients is 14%–33%, varying 
by tumor location and axillary lymph node status [1,3-5]. 
IMN involvement is associated with poor prognosis in breast 
cancer patients, with reported 10-year survival estimates of 
37.3%–62.4% [6-8]. Patients with adverse features such as 
axillary lymphadenopathy, large tumor size, young age, and 
high histologic grade, often undergo magnetic resonance 
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imaging (MRI) and positron emission tomography/computed 
tomography (PET-CT) for staging workup at diagnosis [5]. 
The widespread use of these modern imaging techniques has 
increased the clinical detection of positive IMNs at diagnosis 
[9-11]. 
Historically, surgical dissection and pathological evaluation 
of IMN chains were offered for patients receiving extended 
radical mastectomies [12]. However, this practice declined as 
less aggressive breast conservation surgeries became more 
common [5]. Recently, some surgeons have suggested that 
IMN biopsy provides some clinical benefit [13]. Nonetheless, 
IMNs are frequently undetected in imaging studies, and their 
biopsy or excision is associated with additional complications 
such as vascular injuries, pneumothorax, extended operation 
time, and poor cosmetic outcomes [14,15].
Currently, data on the long-term treatment outcomes of 
clinically IMN-positive patients who receive radiotherapy (RT) 
to the involved area without surgical dissection are scarce. 
Moreover, whether boost irradiation is beneficial and what 
dose should be administered remain unknown. Few studies 
have assessed the clinical outcomes of IMN boost irradiation 
and the optimal radiation dose to radiologically apparent IMNs 
at diagnosis in breast cancer patients. This study aimed to 
review the clinical outcomes of initial clinically IMN-positive 
breast cancer patients treated with RT at our institution. 
Methods and Materials
1. Patients
We retrospectively reviewed data of 95 breast cancer patients 
with clinically detected IMNs at diagnosis treated with surgery 
and RT between June 2009 and December 2015. Of these, 95 
patients with clinically positive IMN detected either by MRI 
or PET-CT were included in the study. Patients were excluded 
from the study if they had an M1 stage at diagnosis, received 
surgical dissection of IMN, did not receive RT to the regional 
lymph nodes, or did not complete RT. For each patient, 
MRIs and PET-CTs performed at diagnosis were reviewed, 
and the number and size of positive IMNs were recorded. 
Patients were considered to have positive IMNs on the basis 
of radiologic reports of pre-treatment MRIs or PET-CTs. IMN 
size was measured by the longest diameter of enlarged IMN 
according to a picture archiving and communications system. 
LN size was measured by MRI or for one patient without MRI, 
by CT images from PET-CT. Tumor characteristics, including 
molecular type and histologic grade, were recorded, along 
with treatment characteristics such as surgery type, resection 
margin, and systemic treatment type (neoadjuvant, adjuvant 
chemotherapy, and hormone therapy). Luminal A type was 
defined as estrogen receptor (ER) and progesterone receptor 
(PR) positive, HER2 negative, and Ki-67 <14%. Luminal B was 
defined as ER positive, HER2 negative, and Ki-67 ≥14% or PR 
negative or low, or as ER and/or PR positive, and HER2 positive. 
Non luminal, HER2 positive was defined as no expression of 
ER and PR and HER2 positive. Triple negative breast cancer 
was defined as ER, PR, and HER2 negative. IMN response 
to neoadjuvant chemotherapy was evaluated by comparing 
the longest diameters of IMN before and after completing 
neoadjuvant chemotherapy according to the RECIST 1.0 
criteria. Complete response was achieved if lymphadenopathy 
was resolved after neoadjuvant chemotherapy, whereas partial 
response was achieved if the longest diameter decreased more 
than 30%.
2. Radiotherapy
Each patient’s clinical chart was reviewed to determine the 
RT field, technique, and schedule. Patients received RT to 
the breast/chest wall and regional lymph nodes in either 
conventional or hypofractionated schedules. Planning CT was 
performed in all patients, and patient immobilization was 
achieved through the use of customized foam positioners 
and thermoplastic masks. Patients received RT as either three-
dimensional conformal radiotherapy (3D CRT) or intensity-
modulated radiotherapy (IMRT). The RT planning techniques 
for 3D CRT included reverse hockey stick, standard tangent 
and anterior beam, partial wide tangential, and photon-
electron mixed fields. The RT planning technique for IMRT 
included partial two-arc volumetric modulated arc therapy 
(VMAT). All boost irradiation was administered as sequential 
boosts in 3D CRT patients and as a simultaneous integrated 
boost in IMRT patients. In the conventional schedule, most 
patients received 50.4 Gy of RT to the whole breast/chest 
wall and regional LNs (axillary LNs level I–III, SCL, IMN) in 28 
fractions and a sequential boost of 5.4–9 Gy to IMNs in 3–5 
fractions. Some received 50 Gy RT to the whole breast/chest 
wall and regional LNs in 25 fractions and a boost of 10 Gy to 
IMNs in 5 fractions. In the hypofractionated schedule, patients 
received 42.56 Gy of RT in 16 fractions to the whole breast/
chest wall and regional LNs and a sequential boost of 10 Gy to 
the IMNs in 2 Gy fractional doses. For IMRT patients, 48 Gy of 
RT in 15 fractions was administered to IMNs, while 40 Gy in 15 
fractions was administered to the whole breast/chest wall and 
regional LNs simultaneously. The decision to prescribe a boost 
dose for IMNs was at the discretion of the treating physicians. 
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The IMN boost target was delineated as a 3-mm margin to the 
initial enlarged IMN according to a fusion of the initial MR 
images with CT simulation images.
3. Toxicity 
The electronic medical records of each patient were reviewed 
to investigate toxicities following IMN irradiation. Adverse 
skin reactions were graded using the Common Terminology 
Criteria for Adverse Events version 4.0 from the National 
Cancer Institute [17]. Grade 1 pulmonary toxicity was defined 
as pneumonitis detected on imaging studies without any 
clinical symptoms. Grade 2 pulmonary toxicity was defined as 
symptomatic pneumonitis. 
4. Analysis
For all recurrent cases, recurrence site and date were recorded. 
The primary endpoint was IMN failure-free survival, which was 
defined as the number of months between the first treatment 
day and the date of follow-up evaluation when IMN recurrence 
was first observed. The first treatment day was defined as the 
start day of neoadjuvant chemotherapy or the operation date 
for patients who did not receive neoadjuvant chemotherapy. 
Table 1 . Patient and treatment characteristics (n = 95)
Characteristic Value
Age (yr) 46 (20–73)
Laterality
  Left 49 (51.6)
  Right 46 (48.4)
Pathology
  IDC 89 (93.6)
  Others 6 (6.4)
cT
  1-2 60 (63.1)
  3-4 35 (36.9)
cN
2b 6 (6.4)
3b 89 (93.6)
IMN+ diagnosis
  MRI 19 (20.0)
  PET + MRI 76 (80.0)
Initial IMN+ size (cm)
  <1 38 (40.0)
  ≥1 57 (60.0)
Histologic grade
  1 or 2 49 (51.6)
  3 32 (33.7)
  Unknown 14 (14.7)
Molecular type
  Luminal A 9 (9.5)
  Luminal B 35 (36.8)
  Non-luminal, HER2+ 25 (26.3)
  TNBC 26 (27.4)
LVI
  No 72 (75.8)
  Yes 23 (24.2)
Neoadjuvant CTx
  No 18 (18.9)
  Yes 77 (81.1)
Neoadjuvant CTx regimen
  AC 3 (3.9)
  AC-T 54 (70.1)
  FAC 4 (5.2)
  Others 16 (20.8)
Adjuvant CTx regimen
  AC-T 11 (37.9)
  FAC 3 (10.3)
  Paclitaxel 3 (10.3)
  Others 12 (41.4)
Surgery
  BCS 22 (23.2)
  Mastectomy 73 (76.8)
Resection margin
  Negative 87 (91.6)
  Close or positive 8 (8.4)
RT modality
  3D CRT 67 (70.5)
  IMRT 28 (29.5)
RT schedule
  Conventional 75 (78.9)
  Hypofractionated 20 (21.1)
IMN boost
  No 83 (87.3)
  Yes 12 (12.7)
IMN boost dose in EQD2 (α/β = 4.0)
  Range 8.7–14.00
  IQR 8.7–12.37
Values are presented as median (range) or number (%).
IDC, invasive ductal carcinoma; IMN, internal mammary lymph 
node; MRI, magnetic resonance imaging; PET, positron emission 
tomography; HER2, human epidermal growth factor receptor 2; 
TNBC, triple-negative breast cancer; LVI, lymphovascular invasion; 
AC, adriamycin-cyclophosphamide; AC-T, adriamycin-cyclophos-
phamide-docetaxel; FAC, fluorouracil-adriamycin-cyclophospha-
mide; BCS, breast-conserving surgery; 3D CRT, three-dimensional 
conformal radiotherapy; IMRT, intensity-modulated radiotherapy; 
IQR, interquartile range.
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The secondary endpoints were disease-free survival (DFS) 
and overall survival (OS). DFS was defined as the number of 
months between the first treatment day and the date when 
any recurrence was noted. Kaplan-Meier comparisons were 
used to estimate IMN failure-free survival, DFS, and OS. All 
statistical analyses were conducted using IBM SPSS Statistics 
for Windows, version 23.0 (IBM Corp., Armonk, NY, USA).
Results
A total of 95 women with a median age of 46 years (range, 
20 to 73 years) were included in the study. Patient and tumor 
characteristics are summarized in Table 1. Of 95 patients, MRI 
and PET-CT were performed at diagnosis for 92 patients; two 
patients had initial MR images only, and one patient had an 
initial PET-CT image only. Nineteen patients (20%) had initial 
IMNs detected only on MRI, and 76 patients (80%) had IMNs 
detectable on PET-CT. In total, 66 patients had a single IMN 
detected, 17 had two IMNs detected, and 12 had more than 
two enlarged IMNs. IMN biopsy was not routinely performed, 
and only two patients underwent IMN biopsy during breast 
surgery. Seventy-seven patients (81%) received neoadjuvant 
chemotherapy, and 73 patients (77%) received mastectomy. 
No patient underwent surgical excision of IMN. Of those who 
received neoadjuvant chemotherapy, 52 (67.5%) showed a 
complete response of IMN after neoadjuvant chemotherapy 
and 19 (24.6%) showed a partial response. All 38 HER2-
positive patients received trastuzumab for at least 1 year 
postoperatively. A total of 51 patients received postoperative 
hormone therapy, including 29 premenopausal patients who 
received tamoxifen and 22 postmenopausal patients who 
received letrozole. 
Table 2. Tumor characteristics of the IMN non-boost and boost groups
IMN boost (–)
(n = 83)
IMN boost (+)
(n = 12) p-value
Age (yr) 0.463
≤40 22 (26.5) 2 (16.7)
>40 61 (73.5) 10 (83.3)
cT 0.458
1–2 51 (61.4) 9 (75.0)
3–4 32 (18.6) 3 (25.0)
Initial IMN size (cm) 0.256
<1 35 (42.2) 3 (25.0)
≥1 48 (57.8) 9 (75.0)
IMN response to neoadjuvant CTx 0.095
Down-staging (+) 54 (77.1) 5 (71.4)
Down-staging (–) 16 (22.9) 2 (28.6)
LVI 0.131
Yes 18 (21.7) 5 (41.7)
No 65 (78.3) 7 (58.3)
Molecular subtype 0.221
Luminal A 9 (10.8) 0 (0)
Luminal B 32 (38.6) 3 (25.0)
Non-luminal, HER2+ 22 (26.5) 3 (25.0)
TNBC 20 (24.1) 6 (50.0)
Histologic grade 0.421
1, 2 44 (62.9) 5 (45.5)
3 26 (37.1) 6 (54.5)
Resection margin 0.271
Negative 77 (92.8) 10 (83.3)
Close or positive 6 (7.2) 2 (16.7)
Values are presented as number (%).
IMN, internal mammary node; CTx, chemotherapy; LVI, lymphovascular invasion; TNBC, triple-negative breast cancer.
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After surgery, all patients received adjuvant RT to the breast 
or chest wall and regional lymph nodes including the IMN 
chain. IMN boost irradiation was performed in 12 patients 
(12.7%). No association between IMN response to neoadjuvant 
chemotherapy and IMN boost RT was noticed in our study. 
The median IMN boost dose was 10 Gy (interquartile range, 
9 to 12 Gy). Sixty-seven patients (70.5%) were treated with 
3D CRT and 28 (29.5%) were treated with IMRT. Patient and 
tumor characteristics of the boost and non-boost groups did 
not differ significantly (Table 2). No differences in initial IMN 
size or response to neoadjuvant chemotherapy were observed 
between the two groups. 
The median follow-up duration from first treatment was 
43.2 months (range, 4.5 to 100.5 months). The 5-year OS 
Fig. 1.  (A) Kaplan-Meier estimates of IMN-control for the entire cohort and (B) overall survival (OS) and disease-free survival (DFS). 
IMN, internal mammary node.
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Fig. 2.  (A) Patient stratification according to initial IMN size and IMN boost radiotherapy. (B) Kaplan-Meier estimate of IMN-control 
among patients with initial IMN ≥ 1 cm without boost RT versus all others. IMN, internal mammary node.
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was 84.2%, and the 5-year DFS was 70.6%, with 24 cases 
of any recurrence reported (Fig. 1). Among 24 cases with 
any recurrence, six patients had locoregional failure, 14 had 
distant metastases, and 4 had both locoregional and distant 
metastases. Only 2 of the 10 locoregional failure cases were 
noted on the chest wall, with the remaining cases experiencing 
recurrence in the regional LN areas. Factors related to DFS 
included initial clinical T stage, IMN response to neoadjuvant 
chemotherapy, lymphovascular invasion, and resection margin. 
IMN boost was not significantly associated with DFS. The 
5-year IMN control probability was 96.4%, and no IMN failure 
was noted in the IMN boost-irradiated group. IMN failures 
were first noted on routine MRIs, and were confirmed through 
PET-CTs. The three cases of IMN failure noted in this study are 
summarized in Table 3. 
In the univariate analysis (Table 4), IMN control was 
significantly associated with close (<2 mm) or positive 
resection margin (p = 0.009). Other factors, including age, 
tumor location, clinical T stage, initial IMN size or number, 
IMN response to neoadjuvant chemotherapy, lymphovascular 
invasion, molecular subtype, and histologic grade, were not 
significantly associated with IMN control. IMN control rates, 
stratified by initial IMN size and IMN boost, are shown in Fig. 
2. Patients with initial IMN size ≥1 cm and who did not receive 
IMN boost irradiation had poorer 5-year IMN control, but the 
difference was not statistically significant (100% vs. 93.2%; 
p = 0.095). No difference in prognosis was observed between 
the 3D CRT and IMRT groups or between the conventional and 
hypofractionated schedule groups (data not shown). 
No adverse effects of grade 3 or higher were reported in 
this study. Higher radiologic lung toxicity (37.5% vs. 5.1%; p 
= 0.003) and mild skin reaction (50.0% vs. 15.3%; p = 0.020) 
were observed in the IMN boost-irradiated patients, but only 
in the 3D CRT group. No adverse reaction of any kind was 
reported following IMN boost with IMRT. No patient presented 
with cardiac toxicity of any grade following RT, and severe 
treatment-related toxicity was not observed regardless of IMN 
boost.
Discussion and Conclusion
Management of the IMN chain in breast cancer patients 
with or without IMN involvement remains controversial, 
as detection and surgical approaches are difficult owing to 
the location. Yet IMN should not be neglected because IMN 
involvement and under-treatment are associated with a poor 
prognosis [18]. Surgical dissection of IMN has been actively 
performed in the past but was abandoned due to lack of 
survival benefit and high potential risk for morbidity [4,19]. 
However, with modern imaging modalities such as MRI and 
Table 3. Summary of cases with IMN failure
Case 1 Case 2 Case 3
Age (yr) 55 31 29
Initial stage cT3N3b cT2N3b cT2N3b
Initial IMN (cm) One, 1.6 cm One, 1.1 cm One, 1 cm
Neoadjuvant CTx AC-T #4 AC-T #4 AC-T #4
IMN response to CTx No visible IMN No visible IMN 0.4 cm IMN
Surgery MRM c ALND MRM c ALND MRM c ALND
yp stage ypT0N0 ypT1N1a ypT2N0
Resection margin Negative Negative Close
Molecular type Lum B, HER2+ TNBC TNBC
Adjuvant CTx/HTx Adjuvant Herceptin None None
Radiotherapy Chest wall, RNI 50 Gy 
without boost
Chest wall, RNI 40 Gy 
without boost
Chest wall, RNI 50 Gy 
without boost
Recurrence site IMN SCL, AXL, IMN, Rt. paratracheal, 
para-aortic, AP window LNs
SCL, AXL, IMN, neck level IV-VI, 
T7 spine, sternum, liver
DFS (mo) 30.7 19.9 25.3
OS (mo) 87.1 36.9 28.4
IMN, internal mammary node; CTx, chemotherapy; AC-T, adriamycin, cyclophosphamide-paclitaxel; MRM, modified radical mastectomy; 
ALND, axillary lymph node dissection; TNBC, triple-negative breast cancer; HTx, hormone therapy; RNI, regional lymph node irradiation; 
SCL, supraclavicular lymph node; AXL, axillary lymph node; AP window, aortopulmonary window; LN, lymph node; DFS, disease-free sur-
vival; OS, overall survival.
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PET-CT, IMN involvement is more frequently observed [5,9,10]. 
This study spotlights the treatment outcomes of initially IMN-
positive breast cancer patients, a topic addressed in few prior 
studies [3,20,21]. 
Our study revealed that RT alone showed excellent long-
term IMN control of initial clinically positive IMNs in breast 
cancer patients without surgical dissection of IMN (5-year 
IMN control: 96.4%). This is concordant with that reported 
by Veronesi et al. [13], who reported that patients with 
positive IMNs showed a 5-year IMN control rate of 95% with 
appropriate systemic treatment and RT. Zhang et al. [3] also 
assessed the outcomes of clinically detected IMNs treated 
with RT, reporting a 5-year IMN control rate of 89%. Historical 
records show a 5-year locoregional control probability of 
93%–96% for surgical dissection of IMN [19], confirming that 
RT alone is an effective treatment strategy for initially positive 
IMNs in breast cancer. 
DFS and OS were also encouraging considering that most 
patients had an initial clinical stage of N3, with a 5-year DFS 
of 70.4% and OS of 84.2%. This is favorable compared to the 
results of historical studies in which the reported OS was 
as low as 30% [22]. Park et al. [20] and Noh et al. [21] also 
reported that the 5-year DFS for patients with initial cN3b 
tumors treated with neoadjuvant chemotherapy, surgery, 
and RT were 60% and 60.2%, respectively. Such improved 
prognosis in the modern era may be attributed to advanced 
systemic therapy and precise local therapy. 
In our study, IMN involvement was determined based 
Table 4. Prognostic factors related to IMN control
No. of patients (%)
Univariate
 5-yr rate (%) p-value
Age (yr) 0.132
≤40 24 (25.3) 91.7
>40 71 (74.7) 98.1
cT 0.942
1–2 60 (63.2) 96.5
3–4 35 (36.8) 96.3
Initial IMN size (cm) 0.156
<1 38 (40.0) 100
≥1 57 (60.0) 94.1
IMN response to neoadjuvant CTx 0.407
Down-staging (+) 59 (76.6) 94.6
Down-staging (–) 18 (23.4) 100
LVI 0.549
No 72 (75.8) 96.9
Yes 23 (24.2) 94.7
Molecular type 0.309
Luminal A 9 (9.5) 100
Luminal B 35 (36.8) 96.7
Non-luminal, HER2+ 25 (26.3) 100
TNBC 26 (27.4) 90.4
Histologic grade 0.062
1, 2 49 (60.5) 100
3 32 (39.5) 92.6
Resection margin 0.009
Negative 87 (91.6) 97.7
Close or positive 8 (8.4) 87.5
IMN boost 0.538
No 83 (87.3) 96.0
Yes 12 (12.7) 100
IMN, internal mammary node; CTx, chemotherapy; LVI, lymphovascular invasion; TNBC, triple-negative breast cancer. 
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only on MR and PET-CT images, and no patient received an 
IMN biopsy prior to treatment. Thus, we cannot exclude the 
possibility of false-positive findings. This practice correlates 
with that in other institutes, wherein IMN involvement is 
examined with radiologic studies or lymphoscintigraphies. 
Detection of IMN with MRI and PET-CT is a noninvasive 
and reliable method, with sensitivities of 93% and 85%, 
respectively, and specificities of 89% and 90%, respectively 
[5,18]. Lymphoscintigraphy is also a valid method for IMN 
mapping, with a reported detection rate of 75%–98%, which 
may be improved with an optimized injection site and tracer 
dose [23]. In contrast, IMN biopsy is technically difficult 
compared to axillary node biopsy and has complication risks, 
including pleural breach and damage to the internal mammary 
vessels [18]. For these reasons, pathological confirmation of 
IMN is not currently routinely performed in many institutes. 
Of the 77 patients who received neoadjuvant chemotherapy, 
over two-thirds (n = 52) showed complete resolution of IMN 
and one-fourth (n = 19) showed a partial response. This is 
consistent with the report by Zhang et al. [3], who revealed 
that 67% and 9.8% of initially IMN-positive patients showed 
complete and partial IMN responses after neoadjuvant 
chemotherapy, respectively. Similar normalization rates of 
IMN and axillary lymph nodes were also reported by Cao et 
al. [24], who revealed that 64.3% of patients with initially 
N+ stage showed N0 stage after neoadjuvant chemotherapy. 
Previous studies and the ongoing NSABP B-51/RTOG 1304 trial 
questioned the necessity of adjuvant RT to the regional lymph 
nodes in breast cancer patients with clinically positive but 
pathologically negative axillary lymph nodes after neoadjuvant 
chemotherapy [25]. In this context, the question arises whether 
we should stratify RT to IMN according to post-neoadjuvant 
chemotherapy status. 
Zhang et al. [3] reported on the institutional outcomes of 
the response-adapted RT policy of MD Anderson by irradiating 
the IMN chain with dose discrimination—60 Gy for IMNs 
normalized after neoadjuvant chemotherapy and 66 Gy for 
grossly remaining IMNs. The IMN control rate was high in both 
the 60 Gy and 66 Gy groups. A study by Yang et al. [26] also 
retrospectively reviewed data of breast cancer patients with 
initially apparent IMN to assess the outcomes of IMN boost 
irradiation. The median dose to the IMN was 62.5 Gy, ranging 
from 50 to 70.4 Gy. In our study, all IMN failure cases were 
noted in patients who did not receive IMN boost irradiation. 
In concordance with our results, Yang et al. [26] reported a 
potential benefit of IMN boost irradiation (5-year DFS 33.3% 
vs. 69.3%; p = 0.019), which was more evident when the initial 
IMN was larger than >1 cm. As such, we believe that IMN 
boost irradiation may be particularly beneficial for patients 
with an initial IMN size of ≥1 cm. However, the optimal boost 
dose remains undetermined. 
No RT-induced severe acute or late toxicities were observed 
in our study, regardless of IMN boost irradiation. Grade 1 
pneumonitis and grade 1 skin reaction were more frequently 
reported in IMN boost irradiated patients, but this increase 
in adverse reactions was observed only when the boost was 
administered in 3D CRT. Despite previous concerns that IMN 
irradiation may cause adverse effects to the heart and lungs 
[27-30], the inclusion of IMN in the RT field resulted in a 
slightly increased incidence of low-grade toxicities and had 
otherwise no clinical relevance. Previous studies also support 
the view that irradiation of the regional lymph nodes not only 
lowers the rates of symptomatic adverse reactions but also 
minimizes the impact on patient performance [28,31]. Modern 
RT techniques, including deep inspiration breathing hold and 
IMRT, may further decrease the radiation dose to the heart 
[32,33]. Our institutional data also demonstrated that IMRT 
decreased grade 1 lung toxicity and skin toxicities of all grades 
following regional lymph node irradiation. Thus, the potential 
benefits of IMN boost irradiation might clinically outweigh 
the risk of adverse effects, given the use of contemporary 
techniques. 
This study has several limitations, partly due to its 
retrospective design. The small study population and narrow 
boost dose range hindered complete statistical analysis of IMN 
irradiation dose on DFS or OS. Moreover, IMN boost irradiation 
was administered according to the treating physicians’ 
discretion, allowing potential selection bias. In addition, the 
follow-up time was not sufficient to assess cardiac toxicities, 
which have been reported to develop as late as 20 years after 
radiation exposure [29]. Despite these limitations, this study 
is one of the largest to evaluate IMN boost irradiation and 
its clinical outcomes. To overcome the study’s shortcomings, 
a multi-center study involving a larger cohort with long-
term follow-up is necessary to completely address the 
clinical benefits and adverse reactions following IMN boost 
irradiation. Considering that the effect of IMN irradiation was 
more apparent when measured as DFS than as locoregional 
recurrence-free survival in previous studies, including the 
MA.20 [27] and EORTC 22922 trials [34], a focus on DFS may 
be more meaningful. 
In conclusion, the results of this study indicate that RT 
alone is effective for the local control of initially positive IMNs 
in breast cancer patients. Moreover, high IMN control with 
RT for IMN-positive breast cancer
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limited treatment toxicity can be achieved with IMRT. Recently, 
the MA.20 [27] and EORTC 22922 trials [34] demonstrated the 
survival benefit of regional lymph node irradiation including 
the IMN chain in breast cancer patients without clinical 
evidence of IMN involvement. In light of such findings, we 
question the potential benefits of boost irradiation for initially 
apparent IMNs. Future studies should focus on identifying 
patients who would most benefit from IMN boost irradiation 
as well as on optimizing the boost irradiation dose. 
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